IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Key Highlights
- ➤Q3 revenue $559,000, up from approximately $260,000 year over year
- ➤FDA requested additional clinical validation information; response expected before January 21, 2027
- ➤Cash, cash equivalents, and restricted cash fell to $11.8 million
- ➤Q3 net loss narrowed to $3.6 million, or $0.10 per share
- ➤GALACTIC registry enrollment began at UCLA, supporting future GraftAssureCore revenue
* Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information * Initiated enrollment into GALACTIC registry study from UCLA Medical Center * Revenue from GraftAssureCore lab-developed test expected to build as GALACTIC enrollment grows * Q3 2026 revenue of $559,000; operating expenses decline as FDA-submission costs wind down * iMDx appoints veteran transplant sales leader to prepare for GraftAssureDx commercial launch NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results:
Innovation and disruption in diagnostics tend to follow a well-known path: A new test starts in a specialized laboratory, becomes used more widely, and eventually becomes a broadly available kit that can be run at local laboratories.
Get started
Create a free account to read the full story.
